Search

everythinglearnresearchcommunity

for

Search:↓

Breast cancer hormone therapy can cause hair loss, which can be treated with daily applications of specific topical solutions like minoxidil and hydrocortisone butyrate.

Cinnamon bark extract may help prevent weight loss and hair loss in breast cancer patients during chemotherapy and is safe to use.

Medicines for enlarged prostate may raise the risk of breast growth and tenderness but not breast cancer.

CDK4/6 inhibitors may cause hair loss in breast cancer patients.

Hormone therapy for breast cancer often leads to sexual issues like vaginal dryness and decreased libido.

Spironolactone does not increase the risk of breast cancer recurrence.

YH0618 granules may help prevent hair loss in breast cancer patients undergoing chemotherapy.

YH0618 granules may help prevent hair loss in breast cancer patients undergoing chemotherapy.

YH0618 granules may help prevent hair loss in breast cancer patients undergoing chemotherapy.

Hair transplant worked for a patient with a specific scalp condition after breast cancer chemotherapy.

Breast cancer survivors often face body image and sexual health issues, needing ongoing support and open communication with healthcare providers.

CK 5/6 expression in breast cancer is linked to negative hormone receptor status and higher tumor grade.

ROR-alpha may increase the growth of certain breast cancer cells by boosting aromatase, which could affect breast cancer prognosis.

Chemotherapy significantly lowers Inhibin A levels in breast cancer patients.

Long-term use of oral contraceptives, especially starting before age 20, may increase the risk of early-onset breast cancer.

Spironolactone is safe for breast cancer survivors with alopecia and does not increase cancer risk.

PLD is an effective and safer alternative for treating breast cancer.

Some breast cancer chemotherapy can cause permanent hair loss.

Some breast cancer patients still experience hair loss three years after chemotherapy, especially with taxane-based treatments.

Using finasteride or dutasteride does not increase the risk of male breast cancer.

Some breast cancer patients developed permanent hair loss after chemotherapy and hormonal therapy, showing patterns similar to common baldness and alopecia areata.

A woman's hair loss was initially mistaken for a common hair loss condition but was later found to be caused by breast cancer cells in her scalp.

Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.

Local hormonal treatment for vulvovaginal atrophy is likely safe for women with estrogen receptor-positive breast cancer on aromatase inhibitors.

No definitive link between finasteride and male breast cancer, but further research is needed.

Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.

Some breast cancer patients on hormonal therapy may develop male or female pattern hair loss, which can sometimes be improved with topical treatments.

The document concludes that modern photo stories help represent and challenge how breast cancer affects women's identities and societal norms.

Finasteride use may increase the risk of male breast cancer.

Finasteride use is not clearly linked to an increased risk of male breast cancer.